Controlled US studies of fenofibrate in the treatment of dyslipidemias

  • G. F. Blane


Data from mostly open, non-comparative European studies indicate that fenofibrate reduces total plasma cholesterol by approximately 20–25% in patients with various types of hyperlipoproteinemias, and reduces total plasma triglycerides by approximately 30–60% in patients with hyperlipoproteinemia. We review here two recent randomized, double-blinded, placebo-controlled clinical trials conducted in the United States which confirmed the European findings, firstly in patients with Type IIa or IIb hyperlipoproteinemia, secondly in patients with type IV or type V hyperlipoproteinemia.


Plasma Lipid Profile Fenofibrate Treatment Total Plasma Cholesterol Concentration Fenofibrate Therapy Fenofibrate Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • G. F. Blane
    • 1
  1. 1.Laboratoires Fournier S.A.Centre de Recherche de DaixFontaine-les-DijonFrance

Personalised recommendations